Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) is now covered by analysts at Guggenheim. They set a "neutral" rating on the stock.
Maravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of Directors
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) was downgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "sell" rating. They now have a $4.25 price target on the stock.
Industry Veteran and Gene Therapy Manufacturing Expert, Ray Kaczmarek, Joins Nanoscope as Chief Technical and Manufacturing Officer [Yahoo! Finance]
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.